Navigation Links
Abbott to Present Data on Novel Cancer Treatments at American Society of Clinical Oncology Annual Meeting
Date:5/15/2008

l-2 proteins, restoring cell death to cancerous cells. Additionally, the compounds were found to enhance the effects of chemotherapy and radiation used to treat other types of cancer, such as non-small cell lung cancer.

Kinase Inhibitors (ABT-869)

Many oncology researchers are currently developing agents that target kinases, a class of enzymes that are often overly activated in cancer cells. Inhibition of the appropriate kinases can suppress tumor growth by cutting off its blood supply.

Discovered by Abbott scientists, ABT-869 is an oral small molecule that provides simultaneously potent and specific inhibition of the VEGFR and PDGFR families that is in Phase I clinical trials for solid tumors and selected hematologic malignancies such as leukemia. Phase II trials for several tumor types began this year.

PARP Inhibitors (ABT-888)

DNA damaging agents remain some of the most successful treatments for cancer. The enzyme Poly(ADP-ribose)polymerase (abbreviated PARP) can help repair DNA damage caused by these agents used to treat cancer and render them ineffective. As PARP activity is often increased in cancer cells, it provides these cells with a survival mechanism.

ABT-888 is an oral PARP-inhibitor developed by Abbott researchers to prevent DNA repair in cancer cells and increase the effectiveness of common cancer therapies such as radiation and alkylating agents.

ABT-888 completed a Phase 0 trial for patients with refractory solid tumors and lymphoid malignancies, and has entered several Phase I trials. Preclinical data indicates ABT-888 has improved the effectiveness of radiation and many types of chemotherapy in animal models of cancer.

About Abbott Oncology

Abbott Oncology is committed to the discovery and development of innovative cancer treatments that enable patients to live longer and healthier lives. Abbott's oncology research is focused on developing more targeted, less toxic therapies than are cu
'/>"/>

SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Abbott to Present at Citi Investment Research Global Health Care Conference
2. Abbott to Present at Morgan Stanley Global Healthcare Unplugged Conference
3. Abbott Announces HUMIRA(R) (adalimumab) Approved in Japan for the Treatment of Rheumatoid Arthritis
4. Abbott Reports Double-Digit Sales and Earnings Growth in First Quarter and Reaffirms Full-Year Growth Outlook
5. Innovative Diagnostic Instrument Introduced by Abbott for Low- to Mid-Volume Laboratory Market Segment
6. Abbott FreeStyle Freedom(R) Lite Blood Glucose Monitoring System Now Available With No Coding for People With Diabetes
7. Abbott Hosts Conference Call for First-Quarter Earnings
8. Takeda, Abbott Announce Plans to Conclude TAP Joint Venture
9. FDA Approves Abbotts FreeStyle Navigator(R) Continuous Glucose Monitoring System
10. Abbott Receives CE Mark for Smaller-Size XIENCE(TM) V Drug Eluting Stent
11. Abbott, Genentech and WEHI Collaborate to Research and Develop New Anti-Cancer Drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... September 30, 2014 World of Children ... founder of the nonprofit, Friends Without A Border (FWAB) ... for building a hospital in Cambodia that has become ... Izu first encountered Cambodia’s appalling lack of pediatric healthcare ... disabilities and illnesses during a photography trip in 1993. ...
(Date:9/30/2014)... 30, 2014 During this online ... approaches to health including achieving hormonal balance, relieving ... and detoxification. , The details ... Date: October 6-9, 2014, Location: Online Event, Registration: ... http://www2.hotzehwc.com/naturalhealthsummitregistration , Monday, October 6th, Steven F. ...
(Date:9/30/2014)... September 30, 2014 AutoTex PINK ... the iconic pink ribbon in support of breast cancer ... month for businesses and non-profits to “go pink” -- ... , AutoTex PINK is a woman-owned company that is ... They are committed to partnering with their customers to ...
(Date:9/30/2014)... September 30, 2014 Timber Home Living Magazine ... for the Olsen family’s reclaimed Douglas fir timber frame home ... home’s journey from architectural planning, to the frame raising, to ... to New Energy Works, after following the timber framing company ... build their dream vacation home on land they fell in ...
(Date:9/30/2014)... Oxnard, CA (PRWEB) September 30, 2014 ... the Anacapa Dental Art Institute in Oxnard and Thousand ... Bangalore today and tomorrow to provide training on full ... previous dental work, placing implants, providing cosmetic dentistry, correcting ... Dr. Jivraj said. , Dr. Jivraj, who has traveled ...
Breaking Medicine News(10 mins):Health News:Nobel Prize For Child Advocates Announces 2014 Health Award Honoree 2Health News:Nobel Prize For Child Advocates Announces 2014 Health Award Honoree 3Health News:Hotze Health & Wellness Center Announces First Natural Health Summit 2Health News:Change Your Blades … Change A Life! AutoTex PINK Wiper Blades Are Helping Wipe Out Breast Cancer 2Health News:Change Your Blades … Change A Life! AutoTex PINK Wiper Blades Are Helping Wipe Out Breast Cancer 3Health News:Reclaimed Timber Frame Home By New Energy Works Featured in Timber Home Living Magazine 2Health News:Reclaimed Timber Frame Home By New Energy Works Featured in Timber Home Living Magazine 3Health News:World-Renowned Dental Implant Expert, International Instructor in India Speaking about Reconstructive Dentistry 2Health News:World-Renowned Dental Implant Expert, International Instructor in India Speaking about Reconstructive Dentistry 3Health News:World-Renowned Dental Implant Expert, International Instructor in India Speaking about Reconstructive Dentistry 4Health News:World-Renowned Dental Implant Expert, International Instructor in India Speaking about Reconstructive Dentistry 5
... 27 (HealthDay News) -- Arizona Congresswoman Gabrielle Giffords began ... forward for the lawmaker who was shot in the ... Memorial Hermann Hospital could last several months. As a ... insert a valve into her breathing tube, the ...
... January 27, 2011 Screening patients in the intensive ... cost savings for the whole hospital, according to a ... the February issue of the American Journal of ... the Association for Professionals in Infection Control and Epidemiology. ...
... , THURSDAY, Jan. 27 (HealthDay News) -- Only 42 ... and can therefore be categorized as "great sleepers," according to ... Poll" found that great sleepers get an average of about ... sleeper gets an average of seven hours and nine minutes ...
... News) -- Electroshock devices, currently classified by the U.S. Food ... severe depression, could be downgraded to medium risk this year. ... to discuss reclassifying the devices, which would pave the way ... illnesses. , , A medium-risk classification would put the devices ...
... continue dating a girlfriend who has cheated on them with ... according to new research from a University of Texas at ... are more likely to continue dating a man who has ... homosexual affair. The study, published last month in the ...
... in China have demonstrated interferon-alpha (IFN-a) is associated with ... erythematosus (SLE). For the first time, IFN-a priming was ... crucial step in plaque build-up. This activation of the ... atherosclerosis risk in SLE. Full findings of this novel ...
Cached Medicine News:Health News:Rep. Giffords' Intensive Rehab Under Way 2Health News:Rep. Giffords' Intensive Rehab Under Way 3Health News:Study finds MRSA screening saves hospitals money 2Health News:Loving Your Bedroom May Be Key to Good Sleep 2Health News:FDA May Ease Up on Electroshock Devices 2Health News:FDA May Ease Up on Electroshock Devices 3Health News:Men more likely to stick with girlfriends who sleep with other women than other men 2Health News:Researchers uncover link to increased atherosclerosis risk in lupus patients 2
(Date:9/30/2014)... , Sept. 30, 2014 CytRx Corporation ... and development company specializing in oncology, today announced ... trial evaluating aldoxorubicin compared to topotecan in subjects ... have relapsed or were refractory to prior chemotherapy. ... chemotherapeutic agent, doxorubicin. CytRx has received Orphan Drug ...
(Date:9/29/2014)... and PARIS , Sept. ... and Sanofi (EURONEXT: SAN and NYSE: SNY) today announced ... investigational therapy that blocks IL-4 and IL-13 signaling, met ... chronic sinusitis with nasal polyps (CSwNP) who did not ... suggest the potential of dupilumab for use in the ...
(Date:9/29/2014)... et SAN DIEGO , ... Ltd. (ci-après désignée Daiichi Sankyo) (TSE : 4568) et ... la conclusion d,un accord de fusion définitif en ... totalité des actions ordinaires en circulation d,Ambit Biosciences ... le biais d,une offre publique d,achat qui sera ...
Breaking Medicine Technology:CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 2CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 3CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 4CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 5Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps 2Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps 3Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps 4Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps 5Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps 6Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps 7Daiichi Sankyo va acquérir Ambit Biosciences 2Daiichi Sankyo va acquérir Ambit Biosciences 3Daiichi Sankyo va acquérir Ambit Biosciences 4Daiichi Sankyo va acquérir Ambit Biosciences 5Daiichi Sankyo va acquérir Ambit Biosciences 6Daiichi Sankyo va acquérir Ambit Biosciences 7Daiichi Sankyo va acquérir Ambit Biosciences 8Daiichi Sankyo va acquérir Ambit Biosciences 9
Used with T-tubes to collect drainage after cholecystectomy. Includes T-tube adapter and two adjustable latex rubber belts....
Used following open gallbladder procedure to drain bile. Often attached to Bard bile bag....
Silicone Flat Hubless Drains...
Bard® Channel Drain...
Medicine Products: